Literature DB >> 8827193

The management of treatment-resistant depression in the medically ill.

K Franco-Bronson1.   

Abstract

There are a few well-designed studies to systematically assess treatment-resistant depression in the medically ill patient. Psychiatrists, however, do have extensive clinical experience in treating depression in the medical patient. This experience can be useful in helping to determine treatment resistance and in selecting consequent treatment choices. A decision tree is offered in Table 1 to clarify the questions the clinician must answer. The first step is to evaluate the role of the medical illness and to decide whether or not treating that effectively will also clear the depression. Physicians may find it helpful to use a decision tree in initiating treatment of patients with depression and physical illness. Once it has been clarified that the diagnosis of depression is a correct one and that an antidepressant medication is in order, consideration of safety, side effects, and other current prescriptions used by the patient must occur. Drug-drug interactions as well as changes in the clearance of medications are critical to the effectiveness of the choice and tolerability for the patient. An antidepressant agent needs to be given for an adequate time with optimization of dosing. Augmenting a medication to increase its therapeutic action could be tried if one agent alone is not effective. An alternative approach is that the second drug selected might affect different neurotransmitters, and the combination of mechanisms would result in resolution of symptoms. Adding psychotherapy, especially when social supports are lacking, can be particularly helpful. ECT is an important consideration for severe depression when suicidal concerns are imminent or the patient has not responded to pharmacotherapy trials. While we await further studies of treatment-resistant depression in large enough numbers of patients with particular illnesses, we can use these guidelines to direct our decisions to switch or augment our initial choices to provide the safest, most effective care possible.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8827193     DOI: 10.1016/s0193-953x(05)70291-4

Source DB:  PubMed          Journal:  Psychiatr Clin North Am        ISSN: 0193-953X


  8 in total

Review 1.  Relapse prevention after index electroconvulsive therapy in treatment-resistant depression.

Authors:  Nagy A Youssef; W Vaughn McCall
Journal:  Ann Clin Psychiatry       Date:  2014-11       Impact factor: 1.567

2.  [Anxiety and anorexia as symptoms of pulmonary disease].

Authors:  S Haack; A Knödler; B Sayour; M Jäger
Journal:  Nervenarzt       Date:  2008-11       Impact factor: 1.214

Review 3.  Integrating co-morbid depression and chronic physical disease management: identifying and resolving failures in self-regulation.

Authors:  Jerusha B Detweiler-Bedell; Michael A Friedman; Howard Leventhal; Ivan W Miller; Elaine A Leventhal
Journal:  Clin Psychol Rev       Date:  2008-09-09

Review 4.  Anxiety in medically ill patients.

Authors:  Rajnish Mago; John-Paul Gomez; Namita Gupta; Elisabeth J S Kunhel
Journal:  Curr Psychiatry Rep       Date:  2006-06       Impact factor: 5.285

Review 5.  A consensus statement for safety monitoring guidelines of treatments for major depressive disorder.

Authors:  Seetal Dodd; Gin S Malhi; John Tiller; Isaac Schweitzer; Ian Hickie; Jon Paul Khoo; Darryl L Bassett; Bill Lyndon; Philip B Mitchell; Gordon Parker; Paul B Fitzgerald; Marc Udina; Ajeet Singh; Steven Moylan; Francesco Giorlando; Carolyn Doughty; Christopher G Davey; Michael Theodoros; Michael Berk
Journal:  Aust N Z J Psychiatry       Date:  2011-09       Impact factor: 5.744

Review 6.  Electroconvulsive therapy and its different indications.

Authors:  Thomas C Baghai; Hans-Jürgen Möller
Journal:  Dialogues Clin Neurosci       Date:  2008       Impact factor: 5.986

7.  Treatment-resistant depression: therapeutic trends, challenges, and future directions.

Authors:  Khalid Saad Al-Harbi
Journal:  Patient Prefer Adherence       Date:  2012-05-01       Impact factor: 2.711

8.  A research study review of effectiveness of treatments for psychiatric conditions common to end-stage cancer patients: needs assessment for future research and an impassioned plea.

Authors:  Ralph J Johnson
Journal:  BMC Psychiatry       Date:  2018-04-03       Impact factor: 3.630

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.